The production of bioactive compounds from traditional Chinese medicine and medicinal plants mainly depends on the extraction and separation from medicinal materials, which is time-consuming, laborious, and requires large amounts of medicinal resources. As the market demand for bioactive compounds increases, the shortage of medicinal resources tops the list. For a stable and sustainable supply of affordable bioactive compounds, it is necessary to optimize chemosynthetic and biosynthetic pathways. Although some progress has been made in chemocatalysis and biosynthesis, there are drawbacks and bottlenecks in current approaches. We hold the opinion that the combination of chemosynthesis and biosynthesis will be the key direction to efficiently produce bioactive compounds. Chemo-enzymatic synthesis, a strategy that combines biosynthesis and chemosynthesis, is an alternative approach for the heterologous production of bioactive compounds. This paper reviews the recent advances in the chemo-enzymatic synthesis of bioactive compounds derived from traditional Chinese medicine and medicinal plants, highlights the potential application, and presents our perspectives for future research.
2 July 2024 in Journal of Integrative Plant Biology
Actinobacteria, the bacterial phylum most renowned for natural product discovery, has been established as a valuable source for drug discovery and biotechnology but is underrepresented within accessible genome and strain collections. Herein, we introduce the Natural Products Discovery Center (NPDC), featuring 122,449 strains assembled over eight decades, the genomes of the first 8490 NPDC strains (7142 Actinobacteria), and the online NPDC Portal making both strains and genomes publicly available. A comparative survey of RefSeq and NPDC Actinobacteria highlights the taxonomic and biosynthetic diversity within the NPDC collection, including three new genera, hundreds of new species, and ∼7000 new gene cluster families. Selected examples demonstrate how the NPDC Portal’s strain metadata, genomes, and biosynthetic gene clusters can be leveraged using genome mining approaches. Our findings underscore the ongoing significance of Actinobacteria in natural product discovery, and the NPDC serves as an unparalleled resource for both Actinobacteria strains and genomes.
Platycodon grandiflorus has been widely used in Asia as a medicinal herb and food because of its anti-inflammatory and hepatoprotective properties. P. grandiflorus has important clinical value because of the active triterpenoid saponins in its roots. However, the biosynthetic pathway of triterpenoid saponins in P. grandiflorus remains unclear, and the related genes remain unknown. Therefore, in this study, we assembled a high-quality and integrated telomere-to-telomere P. grandiflorus reference genome and combined time-specific transcriptome and metabolome profiling to identify the cytochrome P450s (CYPs) responsible for the hydroxylation processes involved in triterpenoid saponin biosynthesis. Nine chromosomes were assembled without gaps or mismatches, and nine centromeres and 18 telomere regions were identified. This genome eliminated redundant sequences from previous genome versions and incorporated structural variation information. Comparative analysis of the P. grandiflorus genome revealed that P. grandiflorus underwent a core eudicot γ-WGT event. We screened 211 CYPs and found that tandem and proximal duplications may be crucial for the expansion of CYP families. We outlined the proposed hydroxylation steps, likely catalyzed by the CYP716A/72A/749A families, in platycodin biosynthesis and identified three PgCYP716A, seven PgCYP72A, and seven PgCYP749A genes that showed a positive correlation with platycodin biosynthesis. By establishing a T2T assembly genome, transcriptome, and metabolome resource for P. grandiflorus, we provide a foundation for the complete elucidation of the platycodins biosynthetic pathway, which consequently leads to heterologous bioproduction, and serves as a fundamental genetic resource for molecular-assisted breeding and genetic improvement of P. grandiflorus.
This review highlights the therapeutic potential of cardiac glycosides and emerging chemical synthesis and biosynthesis strategies to overcome supply limitations.